Cargando…

A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer

Prostate cancer is the most common non-cutaneous cancer among men; yet, current diagnostic methods are insufficient, and more reliable diagnostic markers need to be developed. One answer that can bridge this gap may lie in microRNAs. These small RNA molecules impact protein expression at the transla...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Rhonda, Wu, Qianni, Williams, Vernell, Clark, Gene, Guruli, Georgi, Zehner, Zendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486103/
https://www.ncbi.nlm.nih.gov/pubmed/28621736
http://dx.doi.org/10.3390/ijms18061281
_version_ 1783246202284802048
author Daniel, Rhonda
Wu, Qianni
Williams, Vernell
Clark, Gene
Guruli, Georgi
Zehner, Zendra
author_facet Daniel, Rhonda
Wu, Qianni
Williams, Vernell
Clark, Gene
Guruli, Georgi
Zehner, Zendra
author_sort Daniel, Rhonda
collection PubMed
description Prostate cancer is the most common non-cutaneous cancer among men; yet, current diagnostic methods are insufficient, and more reliable diagnostic markers need to be developed. One answer that can bridge this gap may lie in microRNAs. These small RNA molecules impact protein expression at the translational level, regulating important cellular pathways, the dysregulation of which can exert tumorigenic effects contributing to cancer. In this study, high throughput sequencing of small RNAs extracted from blood from 28 prostate cancer patients at initial stages of diagnosis and prior to treatment was used to identify microRNAs that could be utilized as diagnostic biomarkers for prostate cancer compared to 12 healthy controls. In addition, a group of four microRNAs (miR-1468-3p, miR-146a-5p, miR-1538 and miR-197-3p) was identified as normalization standards for subsequent qRT-PCR confirmation. qRT-PCR analysis corroborated microRNA sequencing results for the seven top dysregulated microRNAs. The abundance of four microRNAs (miR-127-3p, miR-204-5p, miR-329-3p and miR-487b-3p) was upregulated in blood, whereas the levels of three microRNAs (miR-32-5p, miR-20a-5p and miR-454-3p) were downregulated. Data analysis of the receiver operating curves for these selected microRNAs exhibited a better correlation with prostate cancer than PSA (prostate-specific antigen), the current gold standard for prostate cancer detection. In summary, a panel of seven microRNAs is proposed, many of which have prostate-specific targets, which may represent a significant improvement over current testing methods.
format Online
Article
Text
id pubmed-5486103
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54861032017-06-29 A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer Daniel, Rhonda Wu, Qianni Williams, Vernell Clark, Gene Guruli, Georgi Zehner, Zendra Int J Mol Sci Article Prostate cancer is the most common non-cutaneous cancer among men; yet, current diagnostic methods are insufficient, and more reliable diagnostic markers need to be developed. One answer that can bridge this gap may lie in microRNAs. These small RNA molecules impact protein expression at the translational level, regulating important cellular pathways, the dysregulation of which can exert tumorigenic effects contributing to cancer. In this study, high throughput sequencing of small RNAs extracted from blood from 28 prostate cancer patients at initial stages of diagnosis and prior to treatment was used to identify microRNAs that could be utilized as diagnostic biomarkers for prostate cancer compared to 12 healthy controls. In addition, a group of four microRNAs (miR-1468-3p, miR-146a-5p, miR-1538 and miR-197-3p) was identified as normalization standards for subsequent qRT-PCR confirmation. qRT-PCR analysis corroborated microRNA sequencing results for the seven top dysregulated microRNAs. The abundance of four microRNAs (miR-127-3p, miR-204-5p, miR-329-3p and miR-487b-3p) was upregulated in blood, whereas the levels of three microRNAs (miR-32-5p, miR-20a-5p and miR-454-3p) were downregulated. Data analysis of the receiver operating curves for these selected microRNAs exhibited a better correlation with prostate cancer than PSA (prostate-specific antigen), the current gold standard for prostate cancer detection. In summary, a panel of seven microRNAs is proposed, many of which have prostate-specific targets, which may represent a significant improvement over current testing methods. MDPI 2017-06-16 /pmc/articles/PMC5486103/ /pubmed/28621736 http://dx.doi.org/10.3390/ijms18061281 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Daniel, Rhonda
Wu, Qianni
Williams, Vernell
Clark, Gene
Guruli, Georgi
Zehner, Zendra
A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title_full A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title_fullStr A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title_full_unstemmed A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title_short A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer
title_sort panel of micrornas as diagnostic biomarkers for the identification of prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486103/
https://www.ncbi.nlm.nih.gov/pubmed/28621736
http://dx.doi.org/10.3390/ijms18061281
work_keys_str_mv AT danielrhonda apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT wuqianni apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT williamsvernell apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT clarkgene apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT guruligeorgi apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT zehnerzendra apanelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT danielrhonda panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT wuqianni panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT williamsvernell panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT clarkgene panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT guruligeorgi panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer
AT zehnerzendra panelofmicrornasasdiagnosticbiomarkersfortheidentificationofprostatecancer